Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Cardiac magnetic resonance imaging (MRI), Accelerometer physical activity monitoring.
- Who it may be relevant to
- Registry conditions: Cardiotoxicity, Pediatric Cancer, Heart Failure. Basic parameters: 13 years — 39 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
CATCH-HF: Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
Overview
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.
Detailed description
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.
Cardiac remodeling, function, and tissue characteristics will be examined using cardiac MRI in combination with other research assessments to assess the cardiotoxic effects of cancer therapy. Analyses will be performed in a cohort of adolescents and young adults with a history of childhood cancer.
Interventions
- Diagnostic test Cardiac magnetic resonance imaging (MRI)
Cardiac magnetic resonance imaging will be performed to evaluate cardiac remodeling, function, and tissue characteristics - Other Accelerometer physical activity monitoring
Measurement of physical activity using hip-worn accelerometer.
Primary outcome measures
- Left ventricular ejection fraction (LVEF) [Time frame: 3 - 5 years]
Eligibility criteria
Inclusion criteria
- English and Spanish speaking male and female subjects, ages 13-39 years old
- Diagnosis of cancer at age <22 years
- Previously treated with anthracyline therapy for cancer, with diagnosis at least two years prior.
Exclusion criteria
- Patients who have a contraindication to cardiac MRI, including the presence of non-MRI compatible metallic implants.
- Medical, psychiatric, and/or social disorder that would prevent successful completion of planned study testing or would preclude the subject from undergoing the cardiac MRI without anesthesia.
- Patients with a history of congenital heart disease (more significant than a history of patent foramen ovale or patent ductus arteriosus).
- Pregnancy (at the time of enrollment).
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 1 center
- Rady Children's Hospital — San Diego
Publications
- Narayan HK, Chen S, Wong FL, Young N, Qi A, Davis C, Hegde S, Gloude N, Leger KJ, Getz KD, Contijoch F, Ness K, Ky B, Kuo D, Hartman SJ, Armenian SH. The Relationship Between Physical Activity and Left Ventricular Remodeling in Childhood Cancer Survivors Treated With Anthracyclines: A Cross-Sectional Study. Pediatr Blood Cancer. 2026 Jul 25:e70523. doi: 10.1002/1545-5017.70523. Online ahead of pri PMID 42499264
Identifiers
NCT: NCT04262830 · 181758